Dark

Check out our Dark Pool Levels

AKCA
Akcea Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Oct 9, 2020

18.17USD+0.165%(+0.03)815,384

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Oct 30, 2020

07:01AM EDT Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI(r) (inotersen) as PR Newswire

Oct 12, 2020

09:01AM EDT Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics PR Newswire

Sep 26, 2020

04:05AM EDT Ongoing Investigations; Investors are Encouraged to Contact the Firm - AKCA, BLDR, DCOM, STND PR Newswire

Sep 25, 2020

10:35PM EDT SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About PR Newswire

04:55PM EDT (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (NASDAQ: CGIX), Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), Otelco Inc. (NASDAQ: OTEL), Rosetta Stone Inc. (NYSE: RST), Varian Medical Systems, Inc. (NYSE: VAR), and Yintech Investment Holdings Limited (NASDAQ: YIN) PR Newswire

Sep 22, 2020

02:03PM EDT Moore Kuehn Encourages RST, AKCA, DCOM, and SBPH Investors to Contact Law Firm PR Newswire

Sep 16, 2020

01:25PM EDT Lifshitz Law Firm, P.C. Announces Investigation of Aimmune GlobeNewswire Inc

Sep 11, 2020

08:45PM EDT SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA and AIMT Shareholders About Its PR Newswire

Sep 10, 2020

08:50PM EDT Akcea Therapeutics, Inc., BMC Stock Holdings, Inc., Builders FirstSource, Inc., Broadway Financial Corporation, Cancer Genetics, Inc., Proteostasis Therapeutics, Inc., Rosetta Stone Inc., and Yintech Investment Holdings Limited PR Newswire

12:00AM EDT Mergers; Shareholders are Encouraged to Contact the Firm - PRNB, BLDR, AKCA, YIN PR Newswire

Sep 5, 2020

08:30AM EDT Kaskela Law LLC Announces Stockholder Investigation of Akcea Therapeutics, Inc. PR Newswire

Sep 4, 2020

07:49PM EDT AKCEA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akcea Therapeutics, Inc. - AKCA Business Wire

Sep 1, 2020

05:05PM EDT INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Akcea PR Newswire

09:47AM EDT Benzinga's Top Upgrades, Downgrades For September 1, 2020 Benzinga

08:06AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

06:20AM EDT BMO Capital Downgrades Akcea Therapeutics to Market Perform, Lowers Price Target to $18.15 Benzinga

05:35AM EDT (AKCA) Alert: Johnson Fistel Investigates Proposed Sale of Akcea Therapeutics; PR Newswire

Aug 31, 2020

08:21PM EDT SHAREHOLDER ALERT: WeissLaw LLP Investigates Akcea Therapeutics, Inc. PR Newswire

02:30PM EDT Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Regis Shares Drop After Q4 Results Benzinga

01:02PM EDT Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Akcea Therapeutics, Inc. (NASDAQ: AKCA) breached their fiduciary duties or violated the federal securities laws in connection with the companys merger with Ionis Pharmaceuticals, Inc. (NASDAQ: IONS). GlobeNewswire Inc

12:04PM EDT Mid-Day Market Update: Akcea Therapeutics Jumps Following Acquisition News; Acasti Pharma Shares Plummet Benzinga

10:11AM EDT Mid-Morning Market Update: Markets Mostly Lower; Nestl To Acquire Aimmune Therapeutics Benzinga

10:07AM EDT Shares of Akcea Therapeutics, Inc. (AKCA) surged 60% on Monday after Ionis Pharmaceuticals agreed to buy remaining stake in Akcea for $500 million.. RTTNews

08:50AM EDT Looking Into Akcea Therapeutics's Return On Capital Employed Benzinga

06:57AM EDT Ionis To Buy Remaining 24% Of Common Stock Of Akcea It Does Not Already Own For $18.15/Shr Cash RTTNews

06:56AM EDT Akcea Therapeutics to be Acquired by Ionis Pharmaceuticals for $18.15/Share in Cash Benzinga

06:55AM EDT Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics PR Newswire

Aug 29, 2020

04:02AM EDT Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at PR Newswire

03:30AM EDT Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress PR Newswire

Aug 24, 2020

07:10AM EDT Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen at ESC Congress 2020 Benzinga

07:01AM EDT Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L PR Newswire

Aug 18, 2020

07:21AM EDT Akcea, Ionis To Present Phase 2 Results Of AKCEA-APOCIII-L(Rx) In Late-Breaking Presentation At ESC Congress 2020 Benzinga

07:01AM EDT Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in PR Newswire

Aug 13, 2020

07:10AM EDT Akcea Announces New Pricing And Reimbursement Of WAYLIVRA In Germany Benzinga

07:01AM EDT Akcea Announces New Pricing and Reimbursement of WAYLIVRA(r) (volanesorsen) in PR Newswire

Aug 4, 2020

04:37PM EDT Akcea Therapeutics Q2 EPS $(0.49) Misses $(0.35) Estimate, Sales $22.38M Miss $30.93M Estimate Benzinga

04:06PM EDT Akcea Reports Financial Results and Highlights for Second Quarter 2020 PR Newswire

05:19AM EDT Earnings Scheduled For August 4, 2020 Benzinga

Jul 22, 2020

07:10AM EDT Akcea Gets Approval For Reimbursement Of TEGSEDI In Austria For Hereditary Transthyretin Amyloidosis With Polyneuropathy RTTNews

07:09AM EDT Akcea Announces Approval For Reimbursement Of TEGSEDI In Austria For Treatment Of Hereditary Transthyretin Amyloidosis With Polyneuropathy Benzinga

07:01AM EDT Akcea Announces Approval for Reimbursement of TEGSEDI(r) (inotersen) in Austria PR Newswire

Jul 21, 2020

07:01AM EDT Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast PR Newswire

Jul 20, 2020

07:01AM EDT Akcea Appoints New Senior Vice President, Global Medical Affairs PR Newswire

Share